

Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal

CALGARY, Jan 25, 2016 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced the acceptance for publication of a manuscript titled: "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease," in the journal "Atherosclerosis".

The key information in the manuscript details some of the beneficial actions of apabetalone (RVX-208), a bromodomain extra-terminal (BET) protein inhibitor for treating high-risk cardiovascular disease (CVD) patients. The data presented emphasises not only that apabetalone (RVX-208) raises the levels of ApoA-I and HDL, but also that the epigenetic actions of this BET inhibitor can modulate several factors known to be major contributors to CVD risk.

Dr. Norman C.W. Wong, chief scientific officer of Resverlogix stated, "We are pleased to have our data peer reviewed and published in the *Atherosclerosis* journal. This additional recognition helps to further confirm the importance of epigenetics in successfully modulating key CVD pathways."

The accepted manuscript is currently in electronic press and will appear in a future print issue of *Atherosclerosis*. An online version of the manuscript can be accessed at: [http://www.atherosclerosis-journal.com/article/S0021-9150\(16\)30035-1/fulltext](http://www.atherosclerosis-journal.com/article/S0021-9150(16)30035-1/fulltext)

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at <http://www.resverlogix.com/blog> and via Twitter @Resverlogix_RVX https://twitter.com/resverlogix_rvx.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Donald J. McCaffrey
President and CEO
Email: don@resverlogix.com
Tel: 403-254-9252

Sarah Zapotichny
Director of Investor Relations & Corporate Communications
Email: sarah@resverlogix.com
Tel: 403-254-9252

SOURCE Resverlogix Corp.

%SEDAR: 00019253E

CO: Resverlogix Corp.

CNW 13:41e 25-JAN-16